Clinical trials: Carcinoma, Non-Small-Cell Lung
Lung Cancer
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00653250
- Testing
- celecoxib, biopsy, therapeutic conventional surgery
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 41 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Lung Cancer, Nonsmall Cell, Quality of Life
Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer
Lung cancer is the most common type of cancer and the leading cause of cancer death worldwide, in both men and women. Improvements in earlier preoperative staging and more effective adjuvant treatment have improved survival in…
- Conditions
- Lung Cancer, Nonsmall Cell, Quality of Life, Physical Disability, Surgery
- Trial name
- NCT05863013
- Testing
- ADL-Glittre Test
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Centro Universitário Augusto Motta
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy
In this prospective study, the investigators will evaluate and compare the usefulness of functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the palliative chemotherapy with the aim of…
- Trial name
- NCT01482182
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.
- Trial name
- PROGRESS (NCT02804776)
- Testing
- Gefitinib
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- National Cancer Centre, Singapore
NSCLC Stage IV
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously…
- Trial name
- NCT05787613
- Testing
- HLX26, Serplulimab, Chemotherapy drug
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously treated lung cancer that has spread in the body.
- Trial name
- NCT00697060
- Testing
- Imexon + docetaxel
- Where
- 3 sites in United States
- Sponsor
- AmpliMed Corporation
Carcinoma, Non-Small-Cell Lung
The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients
Considering the low expression rate of Melanoma-associated antigen 3 (MAGE-A3) in Asian especially Southeast Asian, it would be great interests to investigate the potential polymorphism of MAGE-A3 in Non-Small-Cell Lung Cancer…
- Trial name
- NCT02714335
- Volunteers
- 200 people
- Sponsor
- Szu-Hua Pan
Non Small Cell Lung Cancer NSCLC
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)
The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT07169708
- Where
- 9 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Non-Small Cell Lung Cancer
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.
- Trial name
- CHANCE (NCT03976518)
- Testing
- Atezolizumab
- Where
- 10 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04466917
- Testing
- ABP 215, Bevacizumab, Paclitaxel
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of…
- Trial name
- NCT05603013
- Testing
- Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.
- Trial name
- NCT01646125
- Testing
- AUY922, Docetaxel, Pemetrexed
- Where
- 27 sites in United States, France and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma, Neuroendocrine Tumours
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity.
- Trial name
- NCT00323076
- Testing
- 18F-FAZA PET Imaging
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- AHS Cancer Control Alberta
Non Small Cell Lung Cancer
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
- Trial name
- NCT03438318
- Testing
- CMP-001, Atezolizumab, Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Cancer, Lung Adenocarcinoma
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this…
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06255197
- Where
- China
- Volunteers
- 60,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer, Non-small Cell Lung Cancer
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with erlotinib (Tarceva®) in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase.
- Trial name
- NCT00692640
- Testing
- XL147 (SAR245408), Erlotinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.